Dilated Cardiomyopathy Therapeutics Market Expected to Reach USD 0.33 billion Globally in 2020
Dilated Cardiomyopathy Therapeutics Market [Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
According to a new market report published by Transparency Market Research "Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global dilated cardiomyopathy market was valued at USD 651.0 million in 2013 and is estimated to reach USD 328.6 million in 2020 declining at a CAGR of (7.0%) from 2014 to 2020.
Browse the full report Dilated Cardiomyopathy Therapeutics Market at http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Dilated cardiomyopathy (DCM) is one of the myocardium disorders associated with cardiac dysfunction. Hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathies represent the four major types of cardiomyopathies, and the others fall under unclassified category. DCM accounts for one of the major causes of heart failure and is characterized by the presence of dilated heart muscles which lead to enlargement of the heart. This in turn, hampers blood pumping capacity of the heart and with time, DCM spreads to the right ventricle, atria and ultimately results in heart failure. The occurrence of dilated cardiomyopathy in males is more prevalent than in females at a ratio of 3:1. Patients with mild DCM can lead normal lives by regular intake of medication along with some lifestyle changes, while patients with severe DCM need a heart transplant.
Oral medications and implantable medical devices constitute the key treatment options for DCM. Oral medications decrease the size of the heart by acting against high...